Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 43

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Mutant p53 exploits enhancers to elevate immunosuppressive chemokine expression and impair immune checkpoint inhibitors in pancreatic cancer

Mahat, Dig B., Kumra, Heena, Castro, Sarah A., Metcalf, Emily, Nguyen, Kim, Morisue, Ryo, Ho, William W., Chen, Ivy, Sullivan, Brandon, Yim, Leon H., Singh, Arundeep, Fu, Jiayu, Waterton, Sean K., Cheng, Yu-Chi, Moiso, Enrico, Chauhan, Vikash P., Silva, Hernandez Moura, Spranger, Stefani, Jain, Rakesh K., Sharp, Phillip A. · 2025 · Immunity

Published version of a preprint

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer characterized by activating KRAS mutations and TP53 alterations. TP53 missense mutations lose their wild-type tumor-suppressor function. Here, we studied whether p53 missense mutations have potential gain-of-function oncogenic roles and their impact on cancer-cell-intrinsic gene expression and the tumor immune microenvironment (TME) in PDAC. p53 R172H established an immunosuppressive TME and impaired the efficacy of immune checkpoint inhibitors (ICIs) by regulating a distinct set of chemokines. Among these, tumor-specific reduction of Cxcl1 , which encodes a chemoattractant for neutrophils, promoted T cell infiltration and decreased tumor growth. Mechanistically, p53 R172H occupied the distal enhancers of Cxcl1 and amplified its expression. These enhancers were responsible for Cxcl1 expression and were essential for its immunosuppressive function. Nuclear factor κB (NF-κB) was a critical cofactor required for p53 R172H occupancy at these enhancers. Thus, a common mutation in a tumor-suppressor transcription factor appropriates enhancers, thereby stimulating chemokine expression and establishing an immunosuppressive TME that diminishes ICI efficacy in PDAC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.immuni.2025.06.005

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Research works printed but not linked: 106

  1. Park, 2021, Pancreatic Cancer: A Review, JAMA, 326, 851, 10.1001/jama.2021.13027 · DOI · Paper page
  2. Royal, 2010, Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma, J. Immunother., 33, 828, 10.1097/CJI.0b013e3181eec14c · DOI · Paper page
  3. Sharma, 2018, Efficacy and tolerability of tremelimumab in patients with metastatic pancreatic ductal adenocarcinoma, J. Clin. Oncol., 36, 470, 10.1200/JCO.2018.36.4_suppl.470 · DOI
  4. O’Reilly, 2019, Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial, JAMA Oncol., 5, 1431, 10.1001/jamaoncol.2019.1588 · DOI · Paper page
  5. Brahmer, 2012, Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer, N. Engl. J. Med., 366, 2455, 10.1056/NEJMoa1200694 · DOI · Paper page
  6. Zheng, 2024, Frontiers and future of immunotherapy for pancreatic cancer: from molecular mechanisms to clinical application, Front. Immunol., 15, 10.3389/fimmu.2024.1383978 · DOI
  7. Kaufman, 2015, Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation, J. Clin. Oncol., 33, 244, 10.1200/JCO.2014.56.2728 · DOI · Paper page
  8. Higuchi, 2015, CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer, Cancer Immunol. Res., 3, 1257, 10.1158/2326-6066.CIR-15-0044 · DOI · Paper page
  9. Reiss, 2022, Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial, Lancet Oncol., 23, 1009, 10.1016/S1470-2045(22)00369-2 · DOI
  10. Hidalgo, 2019, A Multi-Center Phase IIA Trial to Assess the Safety and Efficacy of BL-8040 (a CXCR4 Inhibitor) in Combination with Pembrolizumab and Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma (PDAC), Ann. Oncol., 30, 10.1093/annonc/mdz451 · DOI
  11. Zemek, 2019, Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment, Sci. Transl. Med., 11, 10.1126/scitranslmed.aav7816 · DOI · Paper page
  12. Aggarwal, 2023, First-in-class oral innate immune activator BXCL701 combined with pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC) of small cell neuroendocrine (SCNC) phenotype: Phase 2a final results, J. Clin. Oncol., 41, 10.1200/JCO.2023.41.6_suppl.176 · doi:10.1200/jco.2023.41.6_suppl.176
  13. Zhu, 2015, Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth, Nature, 525, 206, 10.1038/nature15251 · DOI · Paper page
  14. Wang, 2024, Loss-of-Function but Not Gain-of-Function Properties of Mutant TP53 Are Critical for the Proliferation, Survival, and Metastasis of a Broad Range of Cancer Cells, Cancer Discov., 14, 362, 10.1158/2159-8290.CD-23-0402 · DOI · Paper page
  15. Willis, 2004, Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes, Oncogene, 23, 2330, 10.1038/sj.onc.1207396 · DOI · Paper page
  16. Shaulsky, 1991, Alterations in tumor development in vivo mediated by expression of wild type or mutant p53 proteins, Cancer Res., 51, 5232
  17. Cooks, 2013, Mutant p53 Prolongs NF-κB Activation and Promotes Chronic Inflammation and Inflammation-Associated Colorectal Cancer, Cancer Cell, 23, 634, 10.1016/j.ccr.2013.03.022 · DOI · Paper page
  18. Alexandrova, 2015, Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment, Nature, 523, 352, 10.1038/nature14430 · DOI · Paper page
  19. Alexandrova, 2017, p53 loss-of-heterozygosity is a necessary prerequisite for mutant p53 stabilization and gain-of-function in vivo, Cell Death Dis., 8, 10.1038/cddis.2017.80 · DOI
  20. Hanel, 2013, Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis, Cell Death Differ., 20, 898, 10.1038/cdd.2013.17 · DOI · Paper page
  21. Xu, 2011, Gain of function of mutant p53 by coaggregation with multiple tumor suppressors, Nat. Chem. Biol., 7, 285, 10.1038/nchembio.546 · DOI · Paper page
  22. Kim, 2021, Oncogenic KRAS Recruits an Expansive Transcriptional Network through Mutant p53 to Drive Pancreatic Cancer Metastasis, Cancer Discov., 11, 2094, 10.1158/2159-8290.CD-20-1228 · DOI · Paper page
  23. Inga, 2001, p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay, Oncogene, 20, 501, 10.1038/sj.onc.1204116 · DOI
  24. Adorno, 2009, A Mutant-p53/Smad Complex Opposes p63 to Empower TGFβ-Induced Metastasis, Cell, 137, 87, 10.1016/j.cell.2009.01.039 · DOI · Paper page
  25. Mello, 2013, Not all p53 gain-of-function mutants are created equal, Cell Death Differ., 20, 855, 10.1038/cdd.2013.53 · DOI
  26. Amelio, 2020, Context is everything: extrinsic signalling and gain-of-function p53 mutants, Cell Death Discov., 6, 10.1038/s41420-020-0251-x · DOI
  27. Oren, 2024, p53: A tale of complexity and context, Cell, 187, 1569, 10.1016/j.cell.2024.02.043 · DOI
  28. Baugh, 2018, Why are there hotspot mutations in the TP53 gene in human cancers?, Cell Death Differ., 25, 154, 10.1038/cdd.2017.180 · DOI · Paper page
  29. Hassin, 2022, Different hotspot p53 mutants exert distinct phenotypes and predict outcome of colorectal cancer patients, Nat. Commun., 13, 10.1038/s41467-022-30481-7 · DOI
  30. Orth, 2019, Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches, Radiat. Oncol., 14, 10.1186/s13014-019-1345-6 · DOI · Paper page
  31. Maddalena, 2021, TP53 missense mutations in PDAC are associated with enhanced fibrosis and an immunosuppressive microenvironment, Proc. Natl. Acad. Sci. USA, 118, 10.1073/pnas.2025631118 · DOI
  32. Balsano, 2023, Pancreatic Ductal Adenocarcinoma and Immune Checkpoint Inhibitors: The Gray Curtain of Immunotherapy and Spikes of Lights, Curr. Oncol., 30, 3871, 10.3390/curroncol30040293 · DOI
  33. Koikawa, 2021, Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy, Cell, 184, 4753, 10.1016/j.cell.2021.07.020 · DOI · Paper page
  34. Siolas, 2021, Gain-of-function p53R172H mutation drives accumulation of neutrophils in pancreatic tumors, promoting resistance to immunotherapy, Cell Rep., 36, 10.1016/j.celrep.2021.109578 · DOI
  35. Terzian, 2008, The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss, Genes Dev., 22, 1337, 10.1101/gad.1662908 · DOI · Paper page
  36. Suh, 2011, Multiple Stress Signals Activate Mutant p53 In Vivo, Cancer Res., 71, 7168, 10.1158/0008-5472.CAN-11-0459 · DOI
  37. Sullivan, 2018, Mechanisms of transcriptional regulation by p53, Cell Death Differ., 25, 133, 10.1038/cdd.2017.174 · DOI · Paper page
  38. Zhang, 2017, Somatic super-enhancer duplications and hotspot mutations lead to oncogenic activation of the KLF5 transcription factor, Cancer Discov., 8
  39. Basil, 2022, Cistrome and transcriptome analysis identifies unique androgen receptor (AR) and AR-V7 splice variant chromatin binding and transcriptional activities, Sci. Rep., 12, 10.1038/s41598-022-09371-x · DOI
  40. Chiang, 2021, The Function of the Mutant p53-R175H in Cancer, Cancers, 13, 10.3390/cancers13164088 · DOI
  41. Hingorani, 2005, Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice, Cancer Cell, 7, 469, 10.1016/j.ccr.2005.04.023 · DOI · Paper page
  42. Donehower, 2019, Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas, Cell Rep., 28, 1370, 10.1016/j.celrep.2019.07.001 · DOI · Paper page
  43. Jacks, 1994, Tumor spectrum analysis in p53-mutant mice, Curr. Biol., 4, 1, 10.1016/S0960-9822(00)00002-6 · DOI · Paper page
  44. Gopinathan, 2015, GEMMs as preclinical models for testing pancreatic cancer therapies, Dis. Model. Mech., 8, 1185, 10.1242/dmm.021055 · DOI
  45. Morton, 2010, Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer, Proc. Natl. Acad. Sci. USA, 107, 246, 10.1073/pnas.0908428107 · DOI · Paper page
  46. Fischer, 2017, Census and evaluation of p53 target genes, Oncogene, 36, 3943, 10.1038/onc.2016.502 · DOI · Paper page
  47. Giuliano, 2014, The ELR+CXCL chemokines and their receptors CXCR1/CXCR2: A signaling axis and new target for the treatment of renal cell carcinoma, OncoImmunology, 3, 10.4161/onci.28399 · doi:10.4161/onci.28399
  48. Deng, 2021, Glucocorticoid receptor regulates PD-L1 and MHC-I in pancreatic cancer cells to promote immune evasion and immunotherapy resistance, Nat. Commun., 12, 10.1038/s41467-021-27349-7 · DOI
  49. Bardeesy, 2006, Both p16Ink4a and the p19Arf-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse, Proc. Natl. Acad. Sci. USA, 103, 5947, 10.1073/pnas.0601273103 · DOI · Paper page
  50. Peuget, 2024, Translating p53-based therapies for cancer into the clinic, Nat. Rev. Cancer, 24, 192, 10.1038/s41568-023-00658-3 · DOI · Paper page
  51. Parrales, 2015, Targeting Oncogenic Mutant p53 for Cancer Therapy, Front. Oncol., 5, 10.3389/fonc.2015.00288 · DOI · Paper page
  52. Sanford, 2013, Inflammatory Monocyte Mobilization Decreases Patient Survival in Pancreatic Cancer: A Role for Targeting the CCL2/CCR2 Axis, Clin. Cancer Res., 19, 3404, 10.1158/1078-0432.CCR-13-0525 · DOI · Paper page
  53. Gschwandtner, 2019, More Than Just Attractive: How CCL2 Influences Myeloid Cell Behavior Beyond Chemotaxis, Front. Immunol., 10, 10.3389/fimmu.2019.02759 · DOI · Paper page
  54. Kalbasi, 2017, Tumor-Derived CCL2 Mediates Resistance to Radiotherapy in Pancreatic Ductal Adenocarcinoma, Clin. Cancer Res., 23, 137, 10.1158/1078-0432.CCR-16-0870 · DOI · Paper page
  55. Nywening, 2018, Targeting both tumour-associated CXCR2+ neutrophils and CCR2+ macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma, Gut, 67, 1112, 10.1136/gutjnl-2017-313738 · DOI · Paper page
  56. Metelitsa, 2004, Natural Killer T Cells Infiltrate Neuroblastomas Expressing the Chemokine CCL2, J. Exp. Med., 199, 1213, 10.1084/jem.20031462 · DOI · Paper page
  57. Korbecki, 2022, CXCL1: Gene, Promoter, Regulation of Expression, mRNA Stability, Regulation of Activity in the Intercellular Space, Int. J. Mol. Sci., 23, 10.3390/ijms23020792 · DOI
  58. Korbecki, 2022, CXCR2 Receptor: Regulation of Expression, Signal Transduction, and Involvement in Cancer, Int. J. Mol. Sci., 23, 10.3390/ijms23042168 · DOI · Paper page
  59. Fritz, 2022, Editorial: Innate lymphocytes in tumor surveillance, Front. Immunol., 13, 10.3389/fimmu.2022.1093318 · doi:10.3389/fimmu.2022.1093318
  60. Skene, 2017, An efficient targeted nuclease strategy for high-resolution mapping of DNA binding sites, eLife, 6, 10.7554/eLife.21856 · DOI · Paper page
  61. Mahat, 2016, Base-pair-resolution genome-wide mapping of active RNA polymerases using precision nuclear run-on (PRO-seq), Nat. Protoc., 11, 1455, 10.1038/nprot.2016.086 · DOI · Paper page
  62. Tippens, 2020, Transcription imparts architecture, function and logic to enhancer units, Nat. Genet., 52, 1067, 10.1038/s41588-020-0686-2 · DOI
  63. Danko, 2015, Identification of active transcriptional regulatory elements from GRO-seq data, Nat. Methods, 12, 433, 10.1038/nmeth.3329 · DOI · Paper page
  64. Morgan, 2020, Reevaluating the roles of histone-modifying enzymes and their associated chromatin modifications in transcriptional regulation, Nat. Genet., 52, 1271, 10.1038/s41588-020-00736-4 · DOI · Paper page
  65. Timofeev, 2019, Residual apoptotic activity of a tumorigenic p53 mutant improves cancer therapy responses, EMBO J., 38, 10.15252/embj.2019102096 · DOI
  66. Resnick-Silverman, 2023, In vivo RNA-seq and ChIP-seq analyses show an obligatory role for the C terminus of p53 in conferring tissue-specific radiation sensitivity, Cell Rep., 42, 10.1016/j.celrep.2023.112216 · DOI
  67. Tesfaye, 2021, The p53 transcriptional response across tumor types reveals core and senescence-specific signatures modulated by long noncoding RNAs, Proc. Natl. Acad. Sci. USA, 118, 10.1073/pnas.2025539118 · DOI
  68. Liu, 2017, NF-κB signaling in inflammation, Signal Transduct. Target. Ther., 2
  69. Barbie, 2009, Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1, Nature, 462, 108, 10.1038/nature08460 · DOI · Paper page
  70. Camacho, 2009, BLAST+: architecture and applications, BMC Bioinform., 10, 10.1186/1471-2105-10-421 · DOI · Paper page
  71. Rahnamoun, 2017, Mutant p53 shapes the enhancer landscape of cancer cells in response to chronic immune signaling, Nat. Commun., 8, 10.1038/s41467-017-01117-y · DOI
  72. Andrysik, 2017, Identification of a core TP53 transcriptional program with highly distributed tumor suppressive activity, Genome Res., 27, 1645, 10.1101/gr.220533.117 · DOI
  73. Lappalainen, 2021, From variant to function in human disease genetics, Science, 373, 1464, 10.1126/science.abi8207 · DOI · Paper page
  74. Korbecki, 2023, The Clinical Significance and Role of CXCL1 Chemokine in Gastrointestinal Cancers, Cells, 12, 10.3390/cells12101406 · DOI
  75. Yan, 2009, Identification of GRO1 as a Critical Determinant for Mutant p53 Gain of Function, J. Biol. Chem., 284, 12178, 10.1074/jbc.M900994200 · DOI
  76. Li, 2018, Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy, Immunity, 49, 178, 10.1016/j.immuni.2018.06.006 · DOI · Paper page
  77. Yang, 2021, Targeted Deletion of CXCR2 in Myeloid Cells Alters the Tumor Immune Environment to Improve Antitumor Immunity, Cancer Immunol. Res., 9, 200, 10.1158/2326-6066.CIR-20-0312 · DOI
  78. Aggarwal, 2011, NF-κB in Cancer: A Matter of Life and Death, Cancer Discov., 1, 469, 10.1158/2159-8290.CD-11-0260 · DOI · Paper page
  79. Dimitrakopoulos, 2020, The Fire Within: NF-κB Involvement in Non–Small Cell Lung Cancer, Cancer Res., 80, 4025, 10.1158/0008-5472.CAN-19-3578 · DOI
  80. Verzella, 2022, The NF-κB Pharmacopeia: Novel Strategies to Subdue an Intractable Target, Biomedicines, 10, 10.3390/biomedicines10092233 · DOI
  81. Ahn, 2021, Phase separation drives aberrant chromatin looping and cancer development, Nature, 595, 591, 10.1038/s41586-021-03662-5 · DOI · Paper page
  82. Leroy, 2002, p53 gene mutations are associated with poor survival in low and low-intermediate risk diffuse large B-cell lymphomas, Ann. Oncol., 13, 1108, 10.1093/annonc/mdf185 · DOI
  83. Chen, 2022, Mutant p53 in cancer: from molecular mechanism to therapeutic modulation, Cell Death Dis., 13, 10.1038/s41419-022-05408-1 · DOI · Paper page
  84. Liu, 2011, Resuscitating Wild-Type p53 Expression by Disrupting Ceramide Glycosylation: A Novel Approach to Target Mutant p53 Tumors, Cancer Res., 71, 6295, 10.1158/0008-5472.CAN-11-0700 · DOI
  85. Duffy, 2022, Targeting Mutant p53 for Cancer Treatment: Moving Closer to Clinical Use?, Cancers, 14, 10.3390/cancers14184499 · DOI
  86. Gomes, 2021, Structural and Drug Targeting Insights on Mutant p53, Cancers, 13, 10.3390/cancers13133344 · DOI
  87. Hassin, 2023, Drugging p53 in cancer: one protein, many targets, Nat. Rev. Drug Discov., 22, 127, 10.1038/s41573-022-00571-8 · DOI · Paper page
  88. Freed-Pastor, 2012, Mutant p53: one name, many proteins, Genes Dev., 26, 1268, 10.1101/gad.190678.112 · DOI · Paper page
  89. Bianchi, 2023, Cell-autonomous Cxcl1 sustains tolerogenic circuitries and stromal inflammation via neutrophil-derived TNF in pancreatic cancer, Cancer Discov., 13, 1428, 10.1158/2159-8290.CD-22-1046 · DOI
  90. Man, 2022, High expression level of CXCL1/GROα is linked to advanced stage and worse survival in uterine cervical cancer and facilitates tumor cell malignant processes, BMC Cancer, 22, 10.1186/s12885-022-09749-0 · DOI
  91. Yu, 2019, CXCL1 as an Unfavorable Prognosis Factor Negatively Regulated by DACH1 in Non-small Cell Lung Cancer, Front. Oncol., 9
  92. Korbecki, 2023, Involvement in Tumorigenesis and Clinical Significance of CXCL1 in Reproductive Cancers: Breast Cancer, Cervical Cancer, Endometrial Cancer, Ovarian Cancer and Prostate Cancer, Int. J. Mol. Sci., 24, 10.3390/ijms24087262 · DOI
  93. Wang, 2018, CXCL1 derived from tumor-associated macrophages promotes breast cancer metastasis via activating NF-κB/SOX4 signaling, Cell Death Dis., 9
  94. Zhuo, 2022, CXCL1 promotes colon cancer progression through activation of NF-κB/P300 signaling pathway, Biol. Direct, 17, 10.1186/s13062-022-00348-4 · DOI
  95. Cao, 2014, Overexpression of Chemokine (C-X-C) ligand 1 (CXCL1) associated with tumor progression and poor prognosis in hepatocellular carcinoma, Cancer Cell Int., 14, 10.1186/s12935-014-0086-8 · doi:10.1186/s12935-014-0086-8
  96. Hu, 2021, Regulation of tumor immune suppression and cancer cell survival by CXCL1/2 elevation in glioblastoma multiforme, Sci. Adv., 7, 10.1126/sciadv.abc2511 · DOI
  97. Robinson, 2011, Integrative genomics viewer, Nat. Biotechnol., 29, 24, 10.1038/nbt.1754 · DOI · Paper page
  98. Schindelin, 2012, Fiji: an open-source platform for biological-image analysis, Nat. Methods, 9, 676, 10.1038/nmeth.2019 · DOI · Paper page
  99. Langmead, 2009, Ultrafast and memory-efficient alignment of short DNA sequences to the human genome, Genome Biol., 10, 10.1186/gb-2009-10-3-r25 · DOI · Paper page
  100. Yu, 2012, clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters, OMICS A J. Integr. Biol., 16, 284, 10.1089/omi.2011.0118 · DOI · Paper page
  101. Chen, 2013, Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool, BMC Bioinform., 14, 10.1186/1471-2105-14-128 · DOI · Paper page
  102. Han, 2018, TRRUST v2: an expanded reference database of human and mouse transcriptional regulatory interactions, Nucleic Acids Res., 46, D380, 10.1093/nar/gkx1013 · DOI · Paper page
  103. Kent, 2002, The Human Genome Browser at UCSC, Genome Res., 12, 996, 10.1101/gr.229102 · DOI · Paper page
  104. Heinz, 2010, Simple Combinations of Lineage-Determining Transcription Factors Prime cis-Regulatory Elements Required for Macrophage and B Cell Identities, Mol. Cell, 38, 576, 10.1016/j.molcel.2010.05.004 · DOI · Paper page
  105. Li, 2009, The Sequence Alignment/Map format and SAMtools, Bioinformatics, 25, 2078, 10.1093/bioinformatics/btp352 · DOI · Paper page
  106. Martin-Rufino, 2023, Massively parallel base editing to map variant effects in human hematopoiesis, Cell, 186, 2456, 10.1016/j.cell.2023.03.035 · DOI

Cited by

Metadata

Authors
Mahat, D. B., Kumra, H., Castro, S. A., Metcalf, E., Nguyen, K., Morisue, R., Ho, W. W., Chen, I., Sullivan, B., Yim, L. H., Singh, A., Fu, J., Waterton, S. K., Cheng, Y.-C., Moiso, E., Chauhan, V. P., Silva, H. M., Spranger, S., Jain, R. K., & Sharp, P. A.
Venue
Immunity
Publisher
Elsevier BV
Published
2025-07
Volume
58
Issue
7
Pages
1688-1705.e9
ISSN
1074-7613
Cited by
43
References
25
Language
en
Licence
Funders
  • GlaxoSmithKline
  • Nile Albright Research Foundation
  • Howard Hughes Medical Institute
  • National Institutes of Health (R01-NS118929, R01-CA208205, R35-CA197743, U01-CA261842, U01-CA224348, R01-CA259253)
  • Ragon Institute of MGH, MIT and Harvard
  • Japan Society for the Promotion of Science
  • Massachusetts General Hospital
  • National Institutes of Health National Cancer Institute
  • U.S. Public Health Service (R01-GM034277)
  • National Foundation for Cancer Research (R00CA204595-05)
  • Emerald Foundation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.